它的. Portman participating in Johnson & Johnson coronavirus vaccine trial

它的. Portman participating in Johnson & Johnson coronavirus vaccine trial

它的. 罗伯·波特曼, [R-俄亥俄, said on Tuesday that he’s participating in Janssen-Johnson & Johnson’s 新冠病毒 vaccine trial.

The news comes after two other coronavirus vaccines appear close to the finish line — Pfizer-BioNTech reported 90% effectiveness for its vaccine last week, while Moderna reported 94.5% effectiveness for its vaccine on Monday.

TRUMP TOUTS CORONAVIRUS VACCINE ANNOUNCEMENTS ‘ON MY WATCH’: ‘GREAT DISCOVERIES

After getting briefed on the Janssen-Johnson & Johnson phase 3 trial recently by Cincinnati’s own CTI Clinical Trial and Consulting Services, I decided to step forward and enroll in the trial myself,” Portman said in a statement. “I look at it as a way I can play a small role in supporting our country’s health care response to this pandemic. The more people Johnson & Johnson has in the trial, the sooner they can have the complete data they need to finalize this phase of the trial, and move on to the FDA approval process.

它的. 罗伯·波特曼, R-Ohio in 2017. REUTERS/John Sommers II

它的. 罗伯·波特曼, R-Ohio in 2017. REUTERS/John Sommers II

While our country continues to address the ongoing COVID-19 health crisis – which continues to get worse with cases skyrocketing across Ohio – I’ve been encouraged by our progress in developing effective vaccines,” the senator said.

Portman, 64, is enrolled in the ENSEMBLE phase 3 trial at CTI Clinical Trial and Consulting Servicesresearch center in Cincinnati.

的 “large-scale, pivotal, multi-country Phase 3 triallaunched on Sept. 23, 约翰逊 & 约翰逊 announced 当时.

单击此处获取FOX新闻应用程序

I hope that my announcement today will encourage others to feel confident in participating in vaccine clinical trials being conducted across this country,” Portman said in a statement. “I also hope it will reassure people about the safety and effectiveness of vaccines once they have gone through the trials and FDA approval process.”

发表评论

您的电子邮件地址不会被公开. 必需的地方已做标记 *

*